SKB105 for Injection in Advanced Solid Tumors
A phase 1/2 trial of SKB105 for injection Monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
SKB105 for Injection in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07380386 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 256 participants planned, started 2026-03-05 and due to reach its primary completion in 2029-12-31. Interventions recorded: SKB105 for injection Monotherapy.
Similar pages
not linked directly; found by shared links- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB103 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB565 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB118 Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.